2025-10-09 - Analysis Report
Okay, here's an analysis of Salesforce Inc. (CRM) based on the provided data, presented in English with a focus on key figures and interpretations.

## CRM (Salesforce Inc.) Analysis

Salesforce is a global leader in cloud-based software, providing customer relationship management (CRM) services.

### 1. Performance vs. S&P 500 (VOO)

*   **CRM Cumulative Return:** -11.40%
*   **VOO Cumulative Return:** 99.62%
*   **Absolute Divergence:** -109.9
*   **Relative Divergence:** 0.9

**Analysis:** CRM has significantly underperformed the S&P 500 (VOO). The relative divergence of 0.9 suggests this underperformance is near the extreme end of its historical range, indicating potential for future reversion.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD  | Alpha | Beta   | Cap(B) |
|------------|--------|--------|-------|--------|--------|
| 2015-2017  | 39.0% | 70.6% | 10.0% | -0.0 | 97.3   |
| 2016-2018  | 34.0% | 73.5% | 19.0% | 0.1 | 130.4   |
| 2017-2019  | 22.0% | 73.5% | 0.0% | 0.4 | 154.8   |
| 2018-2020  | 14.0% | 73.5% | -10.0% | 0.4 | 211.8   |
| 2019-2021  | 37.0% | 71.9% | -10.0% | 0.7 | 241.9   |
| 2020-2022  | -78.0% | 74.7% | -78.0% | 0.4 | 126.2   |
| 2021-2023  | -47.0% | 76.6% | -49.0% | -0.6 | 250.5   |
| 2022-2024  | -42.0% | 76.6% | -63.0% | -0.4 | 318.3   |
| 2023-2025  | 0.0% | 76.6% | -64.0% | -2.0 | 228.9   |

**Analysis:**

*   **CAGR:**  Growth rates have varied significantly, with strong growth in earlier periods followed by more recent declines.
*   **MDD:** High Maximum Drawdown (MDD) values consistently indicate significant volatility and potential risk.
*   **Alpha:**  Negative alpha values in recent years show that CRM has underperformed relative to its risk (beta).
*   **Beta:** Beta values fluctuate. The recent negative beta might suggest a change in correlation with the overall market.
*   **Cap(B):**  Market capitalization has generally increased over time, indicating overall company growth despite recent performance challenges.

### 2. Recent Stock Price Movement

*   **Current Price:** 240.43
*   **Previous Close:** 239.74
*   **Change:** 0.29
*   **5-Day Moving Average:** 241.04
*   **20-Day Moving Average:** 242.27
*   **60-Day Moving Average:** 248.48

**Analysis:**  The current price is slightly above the previous close, suggesting a minor upward movement. The price is below all three moving averages (5-day, 20-day, and 60-day), which can be interpreted as a short-term downtrend.

### 3. Technical Indicators and Expected Return

*   **MRI:** 0.9 (Medium Investment Recommended)
*   **RSI:** 45.38
*   **PPO:** 0.0519
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** 0.7 (Positive - Short-term increase)
*   **Expected Return:** -4557.4%

**Analysis:**

*   The **MRI** suggests a medium investment recommendation, reflecting moderate risk.
*   The **RSI** of 45.38 is neutral, not indicating overbought or oversold conditions.
*   The **PPO** of 0.0519 is near zero, indicating minimal momentum.
*   The **Hybrid Signal** favors a buy position, further suggesting a potential value opportunity.
*   The **Relative Divergence Change** suggests a recent short-term upward trend.
*   The **Expected Return** is an extremely large negative number, which is unusual and warrants careful scrutiny. It potentially indicates a severe underperformance compared to the S&P 500 over the long term based on the model used to calculate it.

### 4. Recent News & Significant Events

*   **AI Focus:**  News highlights Salesforce's focus on AI adoption, including a $1 billion investment in Mexico. The Zacks article also emphasizes the importance of adapting to AI in the software industry.
*   **Security Incident:** The Drift app hack and Salesforce's refusal to pay a ransom are noteworthy.
*   **Customer Engagement:** The partnership with Haleon using Salesforce Life Sciences Cloud to enhance pharmacy engagement is positive.

**Interpretation:** The news suggests a strategic focus on AI and expanding its global footprint. The security incident could be a concern, but Salesforce's response appears decisive.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.60 (~Buy)
*   **Opinions:** 51
*   **Target Price (avg/high/low):** 334.87 / 430.00 / 221.00

**Analysis:** Analyst consensus is generally positive with a "Buy" rating and a significant average target price above the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-09-04 | 1.97 | 10.24 B$ |
| 2025-05-29 | 1.61 | 9.83 B$ |
| 2024-12-04 | 1.6  | 9.44 B$ |
| 2024-08-29 | 1.48 | 9.32 B$ |
| 2025-09-04 | 1.48 | 9.32 B$ |

**Analysis:** Both EPS and Revenue show a generally increasing trend over the past few quarters, indicating solid financial performance. Note that the date 2025-09-04 is listed twice with differing EPS values, potentially indicating an error in the data.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-07-31 | $10.24B | 78.10%        |
| 2025-04-30 | $9.83B  | 76.96%        |
| 2025-01-31 | $9.99B  | 77.81%        |
| 2024-10-31 | $9.44B  | 77.71%        |
| 2024-07-31 | $9.32B  | 76.85%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE   |
|--------------|----------|-------|
| 2025-07-31 | $61.33B | 3.08% |
| 2025-04-30 | $60.67B | 2.54% |
| 2025-01-31 | $61.17B | 2.79% |
| 2024-10-31 | $58.52B | 2.61% |
| 2024-07-31 | $57.63B | 2.48% |

**Analysis:** Revenue and Equity have generally increased, and Profit Margin has remained strong, suggesting good financial health. ROE has shown an uptrend.

### 7. Overall Assessment

**Summary:**

Salesforce (CRM) has underperformed the S&P 500 significantly, reflected in its negative cumulative return and divergence metrics. While the recent stock price movement indicates a slight increase, it remains below key moving averages. The MRI suggests medium investment risk, and the Hybrid Signal favors a buy position. Recent news highlights the company's focus on AI and global expansion. Analyst consensus is positive with a "Buy" rating and a target price significantly higher than the current price. Earnings and financial data show a generally positive trend, but the extremely negative expected return raises a red flag and should be investigated further.

**Key Considerations:**

*   **Underperformance:**  The substantial underperformance compared to the S&P 500 is a significant concern. Is this due to broader market trends, company-specific issues, or a combination of both?
*   **Expected Return:**  The extremely negative expected return is highly unusual and needs further investigation to determine its accuracy and implications.
*   **AI Strategy:** Salesforce's commitment to AI is a potential catalyst for future growth.
*   **Analyst Sentiment:**  Positive analyst ratings provide some reassurance, but should be considered alongside the other data points.
*   **Risk Factors:** the high MDD values of the alpha, beta analysis over the years could indicate significant volatility and potential risk.

**Recommendation:**

A cautious approach is warranted. While analyst sentiment is positive and the company shows growth in revenue, the underperformance relative to the S&P 500 and the deeply negative expected return are significant concerns. Further research is recommended before making any investment decisions.
